Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships
Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management. Dr. Scanlon also says that there is a lot of variation in the cost and quality of care in oncology. The goal is to identify the appropriate payments for quality care.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
Cancer survivors often encounter a variety of health issues, the most common of which include fatigue, peripheral neuropathy, and depression. To address those specific issues, the American Society of Clinical Oncology (ASCO) has developed 3 new sets of guidelines on cancer survivorship care.
Even as the cost of prescription drugs has plummeted for many Americans, a small slice of the population is being asked to shoulder more and more of the cost of expensive treatments for diseases like cancer and hepatitis C, according to a report to be released on Tuesday by a major drug research firm.
The results of the Phase 3 Prevail Study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.
The American Society of Clinical Oncology (ASCO) today issued three evidence-based clinical practice guidelines on the prevention and management of symptoms that affect many cancer survivors—neuropathy, fatigue and depression, and anxiety. The guidelines are the first three in a planned series of guidelines on survivorship care. The recommendations reinforce the need to care for the both physical and psychological needs of cancer survivors.
Professor Vincenzo Valentini, president of ESTRO and a radiation oncologist at the Policlinico Universitario A. Gemelli, Rome, Italy, commented in a statement: “The results from this trial are important and practice-changing. It is clear that an additional six months of hormonal treatment in addition to radiotherapy improves the outcome for men with localised prostate cancer. This option should now be considered for all these men with prostate cancer that is at risk of growing and spreading.”